Skip to main content
. 2010 Nov 17;28(35):5166–5173. doi: 10.1200/JCO.2010.29.7010

Fig A1.

Fig A1.

Lymphocyte depletion after alemtuzumab treatment in patients with myelodysplastic syndrome. Absolute lymphocyte counts (cells/μL) from complete blood counts in patients at 0, 1, 3, 6, 12, and 24 months after the first dose of alemtuzumab. Each value represents the mean ± SE for all evaluable patients.